RFP
RLAY icon

Root Financial Partners’s Relay Therapeutics RLAY Stock Holding History

Root Financial Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-93
Closed -$925 – 2565
2026
Q1 		$925 Buy
+93
New +$832 ﹤0.01% 2639

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Root Financial Partners's RLAY Position: Q2 2026 in Review

Root Financial Partners sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 93 shares — an estimated $925 sold.

Root Financial Partners first reported a position in RLAY in Q1 2026 and held it in 1 quarter. The position peaked at $925 in Q1 2026. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Root Financial Partners reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 93 Relay Therapeutics shares in Q2 2026, an estimated $925.
  • Root Financial Partners first reported a position in Relay Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Relay Therapeutics position peaked at $925 in Q1 2026.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.